);

A2 Milk boosts China position

Infant formula suppliers The A2 Milk Company and Wattle Health Australia have strengthened their regulatory position in the lucrative Chinese market.

A2 Milk’s application to continue selling its infant formula products in China has been approved by China’s health regulator, the China Food and Drug Administration (CFDA).

Formula manufacturer Synlait Milk, which has been in partnership with A2 Milk since 2010, submitted the mandatory CFDA application in May.

All infant formula manufacturers must register brands and recipes with the CFDA for products to be imported into China from January 1, 2018.

Also, foreign manufacturers of infant formula products in China must register the canning facility used to blend and pack the products with the Certification and Accreditation Administration of People’s Republic of China (CNCA).

From January 1, 2018, all infant formula to be sold in China must be manufactured by a facility accredited by the CNCA, and each facility can only register up to three brands.

Wattle Health has completed its previously announced $5 million acquisition of a 5 per cent interest in Australia infant formula maker Blend & Pack, which is licensed by the CNCA to produce infant formula for China’s market.

A2 Milk shares ended the day on Thursday steady at $5.99, while Synlait Milk gained 49 cents, or 9.1 per cent, to $5.87 and Wattle Health added five cents, or 6.5 per cent to 82.5 cents.

As seen in:
Ballarat Courier, September 29th 2017.
Bendigo Advertiser, September 29th 2017.
Border Mail, September 29th 2017.
Burnie Advocate, September 29th 2017.
Daily Advertiser, September 29th 2017.
Illawarra Mercury, September 29th 2017.
Launceston Examiner, September 29th 2017.
Newcastle Herald, September 29th 2017.
Warrnambool Standard, September 29th 2017.